Rizlife Healthcare

Rizlife Healthcare is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2017, the company is registered as a proprietorship under the Goods and Services Tax (GST) with the number 07AANPF1599E1ZL. The company's headquarters are located at H No 26 E Third Floor, Khizrabad, New Delhi, India. Rizlife Healthcare has a diverse product portfolio, exporting nine products across three therapeutic categories, with a total export value of $81,000 USD and 74 shipments. The top five products contribute 83% to the total export value, indicating a concentrated product focus.

Specific details regarding Rizlife Healthcare's manufacturing facilities, including locations, capacities, and specializations, are not publicly available. The company's export data suggests that it sources its products from various manufacturers, as evidenced by its diverse product range and multiple export shipments. However, without direct information, a comprehensive assessment of its manufacturing capabilities cannot be provided.

Information about the key leadership of Rizlife Healthcare, including the CEO, CFO, and other executives, is not publicly disclosed. The company's export data indicates that Michael Robinson serves as a Sales Representative, with contact details available for business inquiries. However, without further information, a detailed overview of the company's leadership team cannot be provided.

Rizlife Healthcare's export data indicates shipments to various international markets, including the United Arab Emirates, Iraq, and Turkey. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. Without this information, a comprehensive analysis of the company's presence in these regulated markets cannot be conducted.

Rizlife Healthcare's export data indicates shipments to the United Arab Emirates, Iraq, and Turkey. However, specific details regarding the company's penetration in African, Latin American, and Southeast Asian markets, as well as WHO prequalification enabling access, are not publicly available. Without this information, an assessment of the company's presence in these emerging markets cannot be provided.

Rizlife Healthcare's export data indicates shipments to the United Arab Emirates, Iraq, and Turkey. However, without information on the company's overall geographic strategy, diversification efforts, and concentration risks, a comprehensive assessment cannot be conducted.

Specific details regarding Rizlife Healthcare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. Without this information, an assessment of the company's status with the U.S. Food and Drug Administration (FDA) cannot be provided.

Information regarding Rizlife Healthcare's World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. Without this information, an assessment of the company's compliance with these international standards cannot be conducted.

Rizlife Healthcare is registered with the Central Drugs Standard Control Organisation (CDSCO) under the GST number 07AANPF1599E1ZL. However, specific details regarding the company's manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available. Without this information, a comprehensive assessment of the company's compliance with Indian regulatory requirements cannot be provided.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Rizlife Healthcare. Without this information, an assessment of the company's regulatory compliance history cannot be conducted.

Rizlife Healthcare operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. While specific competitors in overlapping categories are not identified, the company's export data indicates that it has engaged in 3,458 export shipments to 43 verified buyers across key markets, including the United Arab Emirates, Iraq, and Turkey. This suggests a competitive presence in these markets. However, without detailed market share data and a head-to-head analysis, a comprehensive competitive landscape assessment cannot be provided.

Rizlife Healthcare's export data indicates a diverse product portfolio, exporting nine products across three therapeutic categories, with a total export value of $81,000 USD and 74 shipments. The top five products contribute 83% to the total export value, indicating a concentrated product focus. However, without information on the company's unique strengths, competitive advantages, and product portfolio distinctions, a comprehensive assessment cannot be conducted.

Rizlife Healthcare's export data indicates shipments to various international markets, including the United Arab Emirates, Iraq, and Turkey. However, without information on the company's overall strategic direction, focus on generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, and future outlook, a comprehensive assessment cannot be provided.

Rizlife Healthcare's export data indicates shipments to various international markets, including the United Arab Emirates, Iraq, and Turkey. However, without information on the company's overall track record, export volume and consistency, and reliability indicators, a comprehensive supplier assessment cannot be conducted.

Specific certifications that importers should verify for Rizlife Healthcare, such as FDA approvals, WHO-GMP, EU GMP, and ISO certifications, are not publicly available. Without this information, guidance on how to verify each certification cannot be provided.

Without specific information on Rizlife Healthcare's certifications, regulatory compliance, and operational practices, a comprehensive due diligence checklist cannot be provided.